A new publication on terlipressin appeared on August 3, 2026 in the journal Frontiers in Pharmacology. The paper is titled "Real-world safety of terlipressin in elderly patients with liver cirrhosis and esophagogastric variceal bleeding: a focus on hyponatremia and administration methods."
The publication addresses real-world safety data for terlipressin use in elderly patients diagnosed with liver cirrhosis and esophagogastric variceal bleeding. According to the title, the study places particular focus on hyponatremia and on methods of administration in this patient population.
No specific findings, results, or conclusions from the study have been provided beyond the publication title and venue. This brief does not characterize or summarize any outcomes, safety signals, or efficacy data, as none were included in the available event information.
Readers interested in the details of the methodology or results should consult the full publication directly through the listed source. For general background on terlipressin, including its approved regulatory status and other context, readers can refer to the compound overview.